Autifony Therapeutics Is A Uk Based Biotechnology Company Focused On Developing Innovative Treatments For Rare And Serious Central Nervous Systemcnsdisordersfounded In 2011 As A Spin Out From Gskthe Company Operates From The Stevenage Bioscience Catalyst In Hertfordshireautifony Specializes In Kv3 Potassium Channel Modulatorsutilizing Its Proprietary Drug Discovery Platform To Address Neurological Hyperexcitability Disorders The Company Has Several Clinical Stage Programsincluding Aut00206Which Has Received Fda Orphan Drug Designation For Fragile X Syndromeand Aut00201Targeting Rare Epilepsy Syndromesadditionallyautifony Is Exploring Preclinical Assets For Conditions Such As Schizophrenia And Age Related Hearing Losswith A Strong Intellectual Property Portfolio Of 27 Patentsautifony Is Positioned As A Pioneer In Ion Channel Therapeuticsaiming To Meet The Needs Of Patients With Limited Treatment Optionsthe Company Has Secured Over $42 Million In Funding And Collaborates With Partners Like Boehringer Ingelheim To Advance Its Cns Therapies
